The Goldman Sachs Group Cuts uniQure (NASDAQ:QURE) Price Target to $9.00

uniQure (NASDAQ:QURE) had its price objective lowered by The Goldman Sachs Group from $10.00 to $9.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a neutral rating on the biotechnology company’s stock.

Several other research analysts have also weighed in on QURE. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of uniQure in a research report on Tuesday, August 20th. Royal Bank of Canada dropped their price objective on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday. Raymond James reaffirmed an “outperform” rating and set a $20.00 price objective on shares of uniQure in a report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 target price on shares of uniQure in a report on Wednesday. Finally, StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $17.00.

uniQure Price Performance

Shares of uniQure stock traded up $0.36 during trading on Wednesday, reaching $7.79. The company’s stock had a trading volume of 791,464 shares, compared to its average volume of 1,411,579. The business has a 50 day moving average price of $5.77 and a 200-day moving average price of $5.82. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The company has a market capitalization of $379.71 million, a P/E ratio of -1.57 and a beta of 0.90. The company has a quick ratio of 7.36, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, sell-side analysts anticipate that uniQure will post -4.1 EPS for the current year.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently modified their holdings of QURE. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new stake in uniQure in the 3rd quarter worth about $53,000. Vanguard Personalized Indexing Management LLC grew its holdings in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of uniQure during the 3rd quarter worth about $69,000. Finally, Total Clarity Wealth Management Inc. acquired a new stake in shares of uniQure in the second quarter worth approximately $74,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.